Skip to main content

Table 1 Summary of patient demographics and kidney transplantation background by treatment group (intent-to-treat population)

From: Efficacy and safety of concentration-controlled everolimus with reduced-dose cyclosporine in Japanese de novo renal transplant patients: 12-month results

  Everolimus 1.5 mg (n= 61) MMF 2 g (n= 61)
Recipient characteristics
Age (years)   
 Mean ± standard deviation 42.5 ± 14.13 38.6 ± 11.36
 Median (range) 42.0 (18 to 65) 36.0 (20 to 64)
Gender, n (%)   
 Male 46 (75.4) 37 (60.7)
 Female 15 (24.6) 24 (39.3)
Body mass index (kg/m2)   
 Mean ± standard deviation 22.46 ± 4.03 21.79 ± 2.78
 Median (range) 21.97 (15.5 to 37.5) 21.09 (16.0 to 27.6)
Primary disease leading to transplantation, n (%)   
 Glomerulonephritis/glomerular disease 16 (26.2) 9 (14.8)
 Polycystic disease 3 (4.9) 3 (4.9)
 Hypertension/nephrosclerosis 5 (8.2) 2 (3.3)
 Diabetes mellitus 3 (4.9) 5 (8.2)
 Interstitial nephritis 2 (3.3) 0 (0.0)
 Obstructive disorder/reflux 6 (9.8) 3 (4.9)
 IgA nephropathy 11 (18.0) 16 (26.2)
 Unknown 8 (13.1) 16 (26.2)
 Other 7 (11.5) 7 (11.5)
Current dialysis   
 None 12 (19.7) 8 (13.1)
 Hemodialysis 42 (68.9) 48 (78.7)
 Peritoneal dialysis 7 (11.5) 5 (8.2)
HLA mismatches   
 1 7 (11.5) 2 (3.3)
 2 9 (14.8) 16 (26.2)
 3 25 (41.0) 24 (39.3)
 <3 16 (26.2) 18 (29.5)
 ≥3 45 (73.8) 43 (70.5)
Donor characteristics
Mean ± standard deviation age (years) 52.3 ± 8.99 55.2 ± 8.23
Deceased heart beating, n (%) 1 (1.6) 0 (0.0)
Deceased nonheart beating, n (%) 0 (0.0) 1 (1.6)
Living related, n (%) 36 (59.0) 43 (70.5)
Living unrelated, n (%) 24 (39.3) 17 (27.9)
  1. HLA, human leukocyte antigen; IgA, immunoglobulin A; MMF, mycophenolate mofetil.